• Explore /
  • Poster
  • / Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

Abstract Video & Slides Poster

Authors

null

Denise A. Yardley

Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN

Denise A. Yardley , Arnd Nusch , Yoon Sim Yap , Gabe S. Sonke , Thomas Bachelot , Arlene Chan , Patrick Neven , Dennis J. Slamon , Paul Wheatley-Price , Agnes Lteif , Manu Sondhi , Karen Rodriguez-Lorenc , Anil Gaur , Stephen K. L. Chia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02422615; NCT02278120

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1054)

DOI

10.1200/JCO.2020.38.15_suppl.1054

Abstract #

1054

Poster Bd #

139

Abstract Disclosures

Similar Posters

First Author: Tomás Pascual

First Author: Coralea Kappel

First Author: Faris Tamimi

First Author: Dan Lv